Agendia NV (Agendia), a subsidiary of Agendia Inc, is a molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products. The company discovers, develops and commercializes products for the treatment of cancer. Its products comprise mammaprint, blueprint, targetprint, coloprint, theraprint for breast cancer, theraprint for colon cancer, and symphony, and among others. Agendia product MammaPrint provides individualized metastasis risk assessment of breast cancer patients. The company collaborates with pharmaceutical companies, cancer centers and academic groups to develop companion diagnostic tests in the area of oncology. It also has a presence in the US, Canada, Spain, Japan, Germany, Mexico, Korea and others. Agendia is headquartered in Amsterdam, Noord-Holland, the Netherlands.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Agendia NV
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Agendia NV Company Overview
Agendia NV Company Snapshot
Agendia NV Pipeline Products and Ongoing Clinical Trials Overview
Agendia NV – Pipeline Analysis Overview
Agendia NV - Key Facts
Agendia NV - Major Products and Services
Agendia NV Pipeline Products by Development Stage
Agendia NV Ongoing Clinical Trials by Trial Status
MammaPrint 70-gene Breast Cancer Recurrence Assay Product Overview
MammaPrint 70-gene Breast Cancer Recurrence Assay Clinical Trial
Treatment Planning Digital Test - Breast Cancer
Treatment Planning Digital Test - Breast Cancer Product Overview
Tumor Cell Percentage Panel
Tumor Cell Percentage Panel Product Overview
Agendia NV - Key Competitors
Agendia NV - Key Employees
Agendia NV - Locations And Subsidiaries
Head Office
Recent Developments
Agendia NV, Recent Developments
Mar 20, 2024: Agendia Announces new Data from I-SPY 2 Showcasing Ability of new Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer
Mar 08, 2024: Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint + BluePrint’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens
Feb 01, 2024: Agendia Announces First Patient Enrolled in DEBRA Trial Using Mammaprint
Sep 28, 2023: New Neoadjuvant Trial Confirms the Predictive Utility of Mammaprint + Blueprint
May 31, 2023: Agendia studies reveal the influence of race on a tumor’s biology, reinforcing its commitment to advancing research of racial disparities in breast cancer
May 31, 2023: Agendia research shows highest risk mammaprint category predicts strongest chemosensitivity in women with early-stage HR+HER2- Breast Cancer
Feb 13, 2023: Updated NCCN Guidelines Recognize MammaPrint UltraLow Risk result, highlighting its clinical utility for women with early-stage breast cancer who can safely forgo toxic treatments with excellent survival rates
Dec 08, 2022: Agendia Level 1B evidence shows MammaPrint is the first and only FDA-cleared gene expression profiling test to predict benefit from extended endocrine therapy in early-stage breast cancer patients
Dec 05, 2022: Agendia spotlights the future of personalized breast cancer care at 2022 San Antonio Breast Cancer Symposium
Jun 05, 2022: Agendia presents data from the FLEX real world evidence trial in seven posters at ASCO 2022, showcasing the power of Its 30,000-patient breast cancer genome project
Table 12: BluePrint 80-Gene Molecular Subtyping Assay - A Study to Evaluate the Addition of Precision to 2018 ASCO/CAP HER2 Testing Guidelines in Breast Cancer with Genomic Profiling
Table 13: BluePrint 80-Gene Molecular Subtyping Assay - MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX)
Table 14: BluePrint 80-Gene Molecular Subtyping Assay - Study to Assess the 12-chemokine Gene Expression Score in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Table 15: BluePrint 80-Gene Molecular Subtyping Assay - Study to Evaluate the High Risk Breast Cancer Genes at 8q22-24 and Their Role in Patients by Using MammaPrint Risk of Recurrence Assay
Table 16: MammaPrint 70-gene Breast Cancer Recurrence Assay - Product Status
Table 17: MammaPrint 70-gene Breast Cancer Recurrence Assay - Product Description
Table 18: MammaPrint 70-gene Breast Cancer Recurrence Assay - A Study to Evaluate the Addition of Precision to 2018 ASCO/CAP HER2 Testing Guidelines in Breast Cancer with Genomic Profiling
Table 19: MammaPrint 70-gene Breast Cancer Recurrence Assay - I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And Molecular Analysis 2)
Table 20: MammaPrint 70-gene Breast Cancer Recurrence Assay - MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX)
Table 21: MammaPrint 70-gene Breast Cancer Recurrence Assay - Multi-institutional Study to Increase Breast Conserving Surgery (BCS) Rate with Personalized Neoadjuvant Strategy in ER Positive and HER2 Negative Breast Cancer Patients for whom BCS is not Feasible
Table 22: MammaPrint 70-gene Breast Cancer Recurrence Assay - Study to Assess the 12-chemokine Gene Expression Score in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Table 23: MammaPrint 70-gene Breast Cancer Recurrence Assay - Study to Evaluate the High Risk Breast Cancer Genes at 8q22-24 and Their Role in Patients by Using MammaPrint Risk of Recurrence Assay
Table 24: Treatment Planning Digital Test - Breast Cancer - Product Status
Table 25: Treatment Planning Digital Test - Breast Cancer - Product Description
Table 26: Tumor Cell Percentage Panel - Product Status